

CEO BOARD UPDATE

Dr Seth Berkley



Gavi/2022/Benedikt v.Loebell

A zero-dose child awaits her first vaccination in the Sundarbans, India



Board meeting
22–23 June 2022

www.gavi.org

In memory of our beloved colleague Danny Graymore OBE


Gavi Board member
representing the United Kingdom,
2016–2019



2022 advocacy, resource mobilisation to close financing for the COVID-19 vaccine equity gap


19 January 2022

Gavi COVAX AMC Investment Opportunity



8 April 2022

Break COVID Now Summit



12 May 2022

2nd Global COVID-19 Summit



US\$ 5.2 billion

in pledges to
COVAX to
accelerate
COVID-19
vaccinations

Recognition for gender equality



Very high scoring organisation

“Seeing [women leaders] in action can be hugely inspirational for staff, setting off a virtuous cycle of women inspiring women. I have seen how women leaders sitting on these boards have the domino effect of dismantling gender stereotypes.”


Anuradha Gupta

Deputy CEO of Gavi, the Vaccine Alliance



March 2022: second re-certification

**GAVI, THE VACCINE ALLIANCE
IS NOW EQUAL-SALARY
RECERTIFIED**



Evaluations: pivotal opportunities for learning, course correction

Completed evaluations



Foreign, Commonwealth
& Development Office

Annual review score “A”
“outputs met expectations”

MOPAN assessment



Network of 21 donor countries to assess Gavi as one of 7 organisations in 2022 assessment cycle; Republic of Korea, Sweden and USA co-chairing new evaluation

Other evaluations in progress/forthcoming

- 1** independent evaluation of **Gavi’s initial response to COVID-19**
- 2** **COVAX Facility & AMC** multi-stage independent evaluations; many more expected
- 3** **centralised evaluations**, including Mid-Term Evaluation (MTE) of Gavi 5.0

Welcome to Catherine Russell

UNICEF's eighth Executive Director
started on 1 February 2022

unicef  | for every child



Welcome to Anne Schuchat ... and thank you to Helen Rees

Incoming and outgoing Chairs
Programme and Policy Committee (PPC)
Gavi Board



Climate change: elevated risk of disease

Famine, forced displacement in East Africa




FAO ramps up support to Sudan farmers as starvation threat grows in East Africa

Post-cyclone cholera outbreaks (2019)



Cholera surges, children in urgent need one month after Idai slammed southern Africa: UNICEF

Increasing temperatures, range of mosquito-borne diseases, viral spillovers



UN health agency launches bid to stop a new global pandemic

nature

Article | [Published: 28 April 2022](#)

Climate change increases cross-species viral transmission risk



GLOBAL ARBOVIRUS INITIATIVE

The New York Times

April 28, 2022

Climate Change Will Accelerate Viral Spillovers, Study Finds


In a warming world, bats in Southeast Asia will be especially prone to spreading viruses to other mammals, researchers found.

Drought, cyclones and arboviruses headlines and photos from UN News (<https://news.un.org>)


CORE PROGRAMMES UPDATE

COVID-19 pandemic & RI disruptions: Asia (SEARO) more impacted than Africa (AFRO)

Weighted relative difference in #DTP3 vaccinated in 2022, 2021 and 2020 compared to 2019



1. 53% of Gavi57 surviving infant population in AFRO represented by countries consistently reporting data through March 2022



2. 97% of Gavi57 surviving infant population in SEARO represented by countries consistently reporting data through December 2021

2021 estimates based on **reported administrative data**; WUENIC data expected mid-July 2022 for definitive assessment on Gavi targets

Aggregate level: 3.8% decline in DTP3 coverage in 2021 versus 2019

Excluding India, Myanmar: 0.7% decrease in DTP3 coverage in 2021 versus 2019

Navigating political, economic instability to restore routine immunisation in Myanmar

Dire situation for routine immunisation

- DTP3 coverage drop from 84% in 2020 to 37% in 2021
(Ministry of Health administrative data; DHIS2)
- Gavi and Alliance partners working to get Expanded Programme on Immunization (EPI) back on track

National COVID-19 immunisation programme

- 25M people (46%) fully immunised; all doses via bilateral procurements & donations
- High coverage rate masking inequities: conflict-affected areas have not received vaccines

March 2022:

- Agreement – between Ministry of Health (military regime), UN & Gavi for equitable immunisation in non-government controlled and conflict-affected regions
 - included pilot COVID-19 vaccination through ICRC & Ethnic Health Organisations (EHOs), supported by Gavi COVAX AMC


May 2022–present:

- Impasse – government refusal to work with EHOs; UN, WHO, UNICEF & Gavi continue dialogue with government on solutions

Penta3 coverage (contains DTP)


2020

Number of townships with
<80% coverage: 90



2021

Number of townships with
<80% coverage: 285




Revamping RI: progress in India through Intensified Mission Indradhanush (IMI 4.0)



Full immunisation coverage (%)

October 2021–March 2022



- Three rounds, starting February 2022*
 - 11 states & UTs**: February–April 2022
 - 22 states & UTs: March–May 2022
- ~6 million children vaccinated by 9 May 2022***
- National Family Health Survey to identify districts with most zero-dose children, highest inequity: >27,000 zero-dose children reached****
- **Interim data** until WUENIC available in July 2022

Sources: *Government of India (GoI) **UTs: Union Territories
IMI 4.0 Portal (all rounds data), GoI *IVB, WHO HQ

Source: HMIS data as of 20 April 2022

Alliance support for Ukraine

COVID-19 vaccines:

- >8.4M doses shipped by 19 January 2022; Ministry of Health (MOH) paused shipments in February after the war began
- ~1.2M doses anticipated to be shipped between July and December 2022 (after MOH requested allocations to resume)

COVAX cold chain equipment (CCE) support:

- To be delivered: 12 walk-in cold rooms; voltage stabilisers; remote temperature monitoring devices (total investment + shipping: ~US \$ 770,000)



First COVID-19 vaccines shipped by COVAX arrive in Ukraine, 16 April 2021

Nigeria: RI progress in Accountability Framework (AF)

AF reviewed; to be refined

- Improvements in national immunisation coverage rates (+23pp for penta3 2016–2021)
- Co-financing obligations met despite fiscal, pandemic challenges
- Varied progress across other indicators

Strategies to support RI

- Development of integrated strategies to reach zero-dose populations
- Investing in building resilient health systems
- Adequate and timely release of government funds
- Strengthening supply chain management

Challenges

- RI system lacks resilience; risk of outbreaks
- Highest # of zero-dose children in Africa
- Reliable COVID-19 vaccine delivery, uptake, demand



Gavi high-level trip to Nigeria (23–25 February 2022) with 62 participants



Gavi/2022/Ozavogu Abdul

Zero-Dose Immunization Programme (ZIP) contracts signed


ZIP is an Equity Accelerator Fund (EAF) initiative

Transformative shift in working with **humanitarian partners, NGOs & CSOs** in settings facing humanitarian crises


New **regional humanitarian partnership** to reach zero-dose children in fragile, conflict and cross-border settings in 11 countries

Gavi funding consortia* led by **World Vision (Sahel)** & **International Rescue Committee (Horn of Africa)**

* **World Vision (Sahel)**: Burkina Faso, Cameroon, Central African Republic, Chad, Mali, Niger, Nigeria;
International Rescue Committee (Horn of Africa): Ethiopia, Somalia, South Sudan, Sudan




Country co-financing trends: 2021 & 2022



● Countries which have paid 2021 co-financing (48)


Despite a challenging fiscal context, 2021 country co-financing obligation for Gavi-supported vaccines fully met
As of 15 March 2022, 100% of countries, excluding six countries granted waivers, fulfilled their obligations

Country co-financing trends: 2021 & 2022



Despite a challenging fiscal context, 2021 country co-financing obligation for Gavi-supported vaccines fully met
As of 15 March 2022, 100% of countries, excluding six countries granted waivers, fulfilled their obligations


Country co-financing trends: 2021 & 2022



- Countries which have paid 2021 co-financing (48)
- Countries which have already met 2022 co-financing (5)
- Countries which have benefited from a full or partial waiver in 2021 (7)

Despite a challenging fiscal context, 2021 country co-financing obligation for Gavi-supported vaccines fully met
As of 15 March 2022, 100% of countries, excluding six countries granted waivers, fulfilled their obligations


Country co-financing trends: 2021 & 2022



- Countries which have paid 2021 co-financing (48)
- Countries which have already met 2022 co-financing (5)
- Countries which have benefited from a full or partial waiver in 2021 (7)
- Country's per capita government health spending expected to drop and remain below pre-COVID-19 levels in 2026:

Despite a challenging fiscal context, 2021 country co-financing obligation for Gavi-supported vaccines fully met
As of 15 March 2022, 100% of countries, excluding six countries granted waivers, fulfilled their obligations


Country co-financing trends: 2021 & 2022



- Countries which have paid 2021 co-financing (48)
- Countries which have already met 2022 co-financing (5)
- Countries which have benefited from a full or partial waiver in 2021 (7)
- Country's per capita government health spending expected to drop and remain below pre-COVID-19 levels in 2026:
- Projected drop of 10–19% in per capita government health spending

Despite a challenging fiscal context, 2021 country co-financing obligation for Gavi-supported vaccines fully met
As of 15 March 2022, 100% of countries, excluding six countries granted waivers, fulfilled their obligations

Country co-financing trends: 2021 & 2022



- Countries which have paid 2021 co-financing (48)
 - Countries which have already met 2022 co-financing (5)
 - Countries which have benefited from a full or partial waiver in 2021 (7)
-
- Country's per capita government health spending expected to drop and remain below pre-COVID-19 levels in 2026:
 - Projected drop of 10–19% in per capita government health spending
 - Projected drop of 20%+ in per capita government health spending

Despite a challenging fiscal context, 2021 country co-financing obligation for Gavi-supported vaccines fully met
As of 15 March 2022, 100% of countries, excluding six countries granted waivers, fulfilled their obligations

Updates on key vaccine programmes

Routine & EPI vaccine programmes

Polio



2022: 10 WPV1 cases;

VDPV2 from environmental surveillance, London, UK

Last 12 months:
>600 cVDPV cases

Priorities: campaign quality;
FPP to target low-performance areas,
integration; adequate supply except nOPV

Outbreak disease programmes

Measles



Past 12 months: 22 large or disruptive outbreaks

Aligning zero-dose agenda & targeted vaccine use

Stockpile diseases



2022 doses approved:

- Oral cholera vaccine: ~14.9M doses (82% of all doses approved in 2022)
- Ebola vaccine: 1,570 doses
- Yellow fever vaccine: >3M doses
- Meningococcal vaccine: >207,000 doses

Evolving & emerging vaccine programmes

HPV




- Coverage decline continues
- Aiding recovery:
 - SAGE one-dose guidance
 - supply improvement

Malaria



- Progress in design, operationalisation of malaria vaccine programme; ongoing assessment of risks
- On Board agenda

Routine & EPI vaccine programmes: polio update



Global WPV1 & cVDPV cases¹, previous 6 months²

● WPV1 cases (latest onset)

Pakistan	8	15.05.22
Mozambique	1	25.03.22
Afghanistan	1	14.01.22

● cVDPV1 cases (latest onset)

Madagascar	5	27.03.22
------------	---	----------

● cVDPV2 cases (latest onset)

DRC	51	06.04.22
Nigeria	27	02.04.22
Mozambique	4	26.03.22
Chad	5	25.03.22
Yemen	55	03.03.22
Niger	2	22.02.22
Somalia	2	18.02.22
Togo	1	21.01.22
Ukraine	1	24.12.21

● cVDPV3 case (latest onset)


Israel	1	12.02.22
--------	---	----------

¹Excludes viruses detected from environmental surveillance; ²Onset of paralysis 15 December 2021 to 14 June 2022

Source: <https://polioeradication.org/polio-today/polio-now/>. Accessed: 21.06.2022.

Measles outbreaks: sub-national mapping to trace under-served communities

Large or disruptive outbreaks (last 12 months)*



Measles outbreaks, when mapped sub-nationally, may be useful tracers for under-served communities, allowing targeted use of Gavi support for outbreak response, HSS and EAF funding windows


*In the frame of tracking progress towards the goals of Immunization Agenda 2030 (IA2030), an indicator has been developed by a working group in order to represent large and disruptive measles outbreaks. This indicator is defined as an incidence equal or greater than 20 reported measles cases per million population over a period of 12 months.

Notes: Based on data received May 2022 and covering period April 2021–March 2022. Incidence: number of cases/1M population. Population data: World population prospects, 2019 revision.

Gavi-supported country	Rate/M
Somalia	531
Liberia	347
Nigeria	106
Yemen	88
Afghanistan	81
Côte d'Ivoire	80
Guinea	58
Mali	57
Cameroon	57
Congo	56
Chad	49
DRC	46
Niger	40
Pakistan	36
Ethiopia	36
Togo	36
CAR	35
Burkina Faso	29
Sudan	24
Mozambique	23
Comoros	21

Measles outbreaks: sub-national mapping to trace under-served communities

Large or disruptive outbreaks (last 12 months)*



Measles outbreaks, when mapped sub-nationally, may be useful tracers for under-served communities, allowing targeted use of Gavi support for outbreak response, HSS and EAF funding windows


*In the frame of tracking progress towards the goals of Immunization Agenda 2030 (IA2030), an indicator has been developed by a working group in order to represent large and disruptive measles outbreaks. This indicator is defined as an incidence equal or greater than 20 reported measles cases per million population over a period of 12 months.

Notes: Based on data received May 2022 and covering period April 2021–March 2022. Incidence: number of cases/1M population. Population data: World population prospects, 2019 revision.

Gavi-supported country	Rate/M
Somalia	531
Liberia	347
Nigeria	106
Yemen	88
Afghanistan	81
Côte d'Ivoire	80
Guinea	58
Mali	57
Cameroon	57
Congo	56
Chad	49
DRC	46
Niger	40
Pakistan	36
Ethiopia	36
Togo	36
CAR	35
Burkina Faso	29
Sudan	24
Mozambique	23
Comoros	21

Measles outbreaks: sub-national mapping to trace under-served communities

Large or disruptive outbreaks (last 12 months)*



Key

Green label (and number) represents ranking of top 10 Gavi68 countries with highest proportion of ZDC (2020 estimates)

Measles outbreaks, when mapped sub-nationally, may be useful tracers for under-served communities, allowing targeted use of Gavi support for outbreak response, HSS and EAF funding windows

*In the frame of tracking progress towards the goals of Immunization Agenda 2030 (IA2030), an indicator has been developed by a working group in order to represent large and disruptive measles outbreaks. This indicator is defined as an incidence equal or greater than 20 reported measles cases per million population over a period of 12 months.

Notes: Based on data received May 2022 and covering period April 2021–March 2022. Incidence: number of cases/1M population. Population data: World population prospects, 2019 revision.

Gavi-supported country	Rate/M
Somalia	531
Liberia	347
Nigeria	106
Yemen	88
Afghanistan	81
Côte d'Ivoire	80
Guinea	58
Mali	57
Cameroon	57
Congo	56
Chad	49
DRC	46
Niger	40
Pakistan	36
Ethiopia	36
Togo	36
CAR	35
Burkina Faso	29
Sudan	24
Mozambique	23
Comoros	21

Ebola virus disease: Democratic Republic of the Congo

21 April 2022: 14th Ebola outbreak notified in DRC

To date: 5 fatal cases reported

3 July 2022: Declared over if no new confirmed cases

Rapid response:

27 April: vaccination initiated with leftover Ervebo from previous shipment

6 May: ICG approval of new shipment

To date: 1,628 individuals vaccinated


2021: 3 outbreaks, rapidly contained



Gavi/2019/Frédérique Tissandier

Recent increase in oral cholera vaccine (OCV) outbreak response; yellow fever, meningococcal steady

Quarterly number of doses approved by ICG




Note: Ebola doses in thousands (4,800 doses in Q4-2021 & 1,570 in Q2-2022) versus other stockpile antigens in millions.

- **Large OCV vaccination campaigns launched** in countries (e.g. Nigeria, Ethiopia, Pakistan, Bangladesh) following confirmation of cholera outbreaks & areas affected by conflict and natural disasters (e.g. cyclones)
- Gavi working to **shift focus to *preventive* OCV campaigns**, facilitated by **improved diagnostic testing for better targeting**, understanding of cholera risks

HPV vaccine programme: coverage challenges continue; SAGE single-dose guidance could be instrumental for recovery/expansion

HPV vaccine coverage in countries that have introduced*



Key challenges

COVID-19: de-prioritisation, disruption & delays


Supply constraints: delayed vaccine introductions, catch-up campaigns

Challenges in health care delivery to adolescents (e.g. pandemic-related school closures)

*Preliminary average coverage data: aggregated by income levels, regions and Gavi eligibility (n=75 countries). Source: IVB database, 2021 eJRF draft estimates. Full eJRF due July 2022. Gavi analysis to be done concurrently with WUENIC update available in July 2022.


Vaccine living assessment for diseases of epidemic & pandemic potential: monkeypox

Per Gavi Board guidance (2018)



Source: Airfinity (dated: 20220621, 1317hr CEST)

Total confirmed cases: 2,781
across 54 countries



Source: WHO (dated: 20220615, 1700hr CEST)

Total confirmed cases: 2,103
across 42 countries

Endemic in 11 African countries (including 10 Gavi-supported countries)*
Since January 2022, there have been 109 confirmed and 1,488 suspected cases of monkeypox**

*WHO ** Based on latest data from Africa CDC (Accessed 20.06.2022)

Assessment:

- **Not currently recommended to support a monkeypox vaccine stockpile for Gavi-supported countries** (for health care workers or close contacts aged <50 years) due to relatively limited burden in endemic countries
- **Situation to be monitored closely due to rapid evolution of disease globally and increased cases/surveillance in AFRO**
- **Recommendation may be updated as more information becomes available**
- **23 June:** WHO meeting to determine PHEIC
- **Gavi: engaging with partners** to identify how to best support global efforts to **contain monkeypox equitably**

Leveraging, scaling up innovations for programmatic impact: digital health information strategy

Criteria to prioritise six digital health information interventions

Interventions aligned with Gavi's mission & comparative advantage

Unmet needs in Gavi-supported countries

Evidence & high return on investment



Identifying, reaching zero-dose & under-immunised children

GIS, digital microplans, birth notification, satellite identification of settlements



Effective sub-national data use

integration of data sources, interactive dashboards



Digital Supply Chain Information System

eLMIS, remote temperature monitoring, enhanced visibility of health facility stock data



Digital interventions supporting vaccine confidence, demand for immunisation

mobile app, SMS, AEFI electronic monitoring



Real-time campaign planning, monitoring

daily monitoring of coverage, stock and AEFI data; interactive dashboards



Electronic VPD surveillance data exchange for targeted vaccination & outbreak response

integrated electronic surveillance systems, from case notification to lab investigation

Acronym list: GIS – geographic information system; eLMIS – electronic logistics management information system; AEFI – adverse events following immunisation

From strategy to operationalisation: supporting Cambodia in planning investment for Digital Health Information

Catalytic investments building on other funding

Building on malaria programme investments in GIS



Identification and reach of zero-dose & under-immunised children

Satellite identification of settlements for better population estimation

Expand from COVID-19 to routine immunisation



Digital supply chain information system

Expand vaccine management system to evolve into eLMIS and real-time temperature monitoring system

Support sustainable solution & scale up an effective intervention




Effective sub-national data use

with integration of data sources, interactive dashboards

Comprehensive Vaccine Management (CVM): strengthening programme efficiency, equity

Gavi-funded vaccines: 2021 year-end stock adequacy (aggregate level)




Key highlights

- 1 Course correction: cross-Alliance efforts to improve stock visibility systems, efficiency
- 2 Significant variations in stock adequacy pose programmatic (equity, efficiency) and financial risks to Gavi and countries
- 3 Efforts to strengthen CVM through forecasting and supply planning; data use; stock management practices; governance; wastage tracking/mitigation (*all linked to Alliance's updated immunisation supply chain strategy*)

Source: 2021 year-end stock for vaccine renewals reported by 50 Gavi-supported countries

CCEOP has procured nearly 70,000 units since 2017, addressing half of all health facility needs in Gavi-supported countries

ILRs and SDDs procured and installed between 2017 & March 2022




Source: UNICEF, 2017 – Q1 2022 KPI

- CCEOP installations continued to scale up in 2021 despite COVID-19 pandemic
- **50% of estimated health facility-level refrigerator needs now met**
- **60% of units solar-powered**, enabling countries to provide services in off-grid facilities, better reach zero-dose children
- Recently completed CCEOP evaluation:
 - **Improvements** in storage capacity; EPI service provision; CCE planning, management
 - **Challenges** in service bundle cost; price sensitivity; maintenance; warranty utilisation
- **Delays in 5.0 applications remain a challenge**


COVAX UPDATE

COVAX achievements



Despite overall progress, increased coverage uneven across COVAX AMC; high-risk populations still not fully reached as priority

COVID-19 vaccination coverage with complete primary series¹



1. Two AMC economies not vaccinating: DRPK and Eritrea; countries with concerted support (CCS)

Source: WHO COVID-19 Vaccine Dashboard; data as of 16 June 2022

Older adult coverage

60%

average

Decrease driven by methodology changes

Health care worker coverage

74%


average

+0% since end March 2022

COVID-19 vaccine pipeline continues to develop; COVAX continues to monitor developments, update portfolio strategy

- R&D pipeline continues to search for vaccines that can better protect against transmission, infection and disease
 - In **near term**, search focuses largely on **variant-adapted and multivalent vaccines**
 - In **mid- to longer term**, focus shifting to **broadly protective coronavirus vaccines**, as well as new innovations such as delivery strategy (mucosal, nasal, oral, etc.)
- As uncertain trajectory of pandemic continues to unfold, there may be need for such vaccines
- **COVAX will continue to monitor R&D pipeline, including through CEPI's investments, and will continue to adjust its portfolio strategy** – including through procurement of new vaccines via Pandemic Vaccine Pool, if and when needed


Current development pipeline of COVID-19 variant-specific vaccines¹



1. Source: CEPI, June 2022. Based on publicly available information from vaccine candidates based on variants.

LOOKING AHEAD

Gavi 5.1: evolution of Gavi 5.0 in context of pandemic, COVAX lessons




Four themes to be explored

- Implications of COVID-19 pandemic (vaccination, learnings, impact on RI) on Gavi's strategic priorities
- Possible design of a COVID-19 vaccine programme, aligning future COVID-19 vaccine support with core Gavi programmes
- Building on Gavi's historic contributions to pandemic preparedness and response (PPR) and new learnings from COVID-19, how Gavi's role in PPR might evolve
- Evolution of Gavi's integrated organisational setup, business processes

Pandemic preparedness & response


Gavi's inherent role in PPR

- **Core mandate:** country-driven approach, drive for vaccine equity, reaching zero-dose children and missed communities
- **Active engagement:** offering actionable insights, solutions and innovations from COVAX and Gavi core programmes – unique contributions, capabilities



Post-pandemic global health architecture

- **Ongoing G7, G20, WHO discussions:** strong focus on equity agenda in health emergency preparedness and response



The First G20 Health Ministerial Meeting, Strengthening Global Health Architecture, Indonesia, 21-22 June 2022.

GAVI SECRETARIAT UPDATE



Super-charging Alliance communications


Gavi countries:

- 36,000 media mentions in 2021 (100% increase over 2020)
- 30 countries covered by Gavi writers' network
- Growth in francophone content on Gavi.org's VaccinesWork portal

Global:

- 53 million minutes of video watched on Gavi's Facebook page in 2021
- 150,000 new followers of Gavi's social media channels in 2021 (including leadership)
- 192,000 media mentions in 2021 (versus 10,000 in 2019)
- 65 op-eds and 96 speeches in 2021
- 2,400 interviews & media responses in 2021

Cross-Secretariat strategic communications



Digital media strategy



Gavi Secretariat developments

Welcome Lucy Elliott, A&I MD

- New Managing Director for Audit & Investigations function
- Replaced Simon Lamb, who retired



Welcome David Marlow, COO

- New position created: Chief Operating Officer
- Starts 4 July



Welcome to our new directors

- **David Kinder**, Development Finance
- **Jalaa' Abdelwahab**, Vaccine Programmes
- **Richard Mihigo**, COVID-19 Vaccine Delivery Team (in Country Programmes)
- **Anamaria Bejar**, Public Policy Engagement (PPE)

Aurélia Nguyen
transitioning out of
COVAX MD role;
Derrick Sim is Acting

Reconfiguration to create two distinct, new departments:

- **Policy, Programme Design and Delivery Support:** MD recruitment launched
- **Vaccine Markets and Health Security:** MD recruitment launched

Gavi Secretariat developments

Return to office; health & wellbeing

- Two days per week in office
- March 2022 staff pulse survey:
 - 6 of 9 categories improved (esp. “Feedback” & “My Manager”); “Wellbeing & Inclusion” improved but lowest-scoring
 - Great mission, feeling of personal accomplishment
 - To be addressed: unsustainable workload, high stress levels

Return to duty travel

- Country visits to elevate zero-dose agenda, address routine immunisation disruptions
- High-level missions planned amid challenging travel landscape

Diversity & inclusion initiatives

- Onward consultancy: defining action plan, affinity groups
- First #GaviPride logo



Garden of Remembrance at Global Health Campus

Tree dedication on 28 June, in memory of two beloved colleagues we lost in 2021

Thank you

